KR20230004543A - 조성물 및 방법 - Google Patents

조성물 및 방법 Download PDF

Info

Publication number
KR20230004543A
KR20230004543A KR1020227037511A KR20227037511A KR20230004543A KR 20230004543 A KR20230004543 A KR 20230004543A KR 1020227037511 A KR1020227037511 A KR 1020227037511A KR 20227037511 A KR20227037511 A KR 20227037511A KR 20230004543 A KR20230004543 A KR 20230004543A
Authority
KR
South Korea
Prior art keywords
binding protein
composition
free light
light chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037511A
Other languages
English (en)
Korean (ko)
Inventor
로잔 던
아루나쿠마리 알라하리
Original Assignee
해마로직스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900948A external-priority patent/AU2020900948A0/en
Application filed by 해마로직스 리미티드 filed Critical 해마로직스 리미티드
Publication of KR20230004543A publication Critical patent/KR20230004543A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
KR1020227037511A 2020-03-27 2021-03-26 조성물 및 방법 Pending KR20230004543A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020900948 2020-03-27
AU2020900948A AU2020900948A0 (en) 2020-03-27 Composition and method
US202163200752P 2021-03-25 2021-03-25
US63/200,752 2021-03-25
PCT/IB2021/000171 WO2021191684A1 (en) 2020-03-27 2021-03-26 Composition and method

Publications (1)

Publication Number Publication Date
KR20230004543A true KR20230004543A (ko) 2023-01-06

Family

ID=77890984

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037511A Pending KR20230004543A (ko) 2020-03-27 2021-03-26 조성물 및 방법

Country Status (9)

Country Link
US (3) US20240262928A1 (https=)
EP (1) EP4126900A4 (https=)
JP (1) JP7817945B2 (https=)
KR (1) KR20230004543A (https=)
CN (1) CN115551877A (https=)
AU (1) AU2021244846A1 (https=)
BR (1) BR112022019076A2 (https=)
CA (1) CA3176109A1 (https=)
WO (1) WO2021191684A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
US20120114555A1 (en) * 2009-04-07 2012-05-10 Immune System Therapeutics Ltd Method for treating immune disorders
ES2982297T3 (es) * 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
BR112017022838A2 (en) * 2015-04-23 2018-07-17 Haemalogix Pty. Ltd kappa myeloma antigen chimeric antigen receptors and their uses
EP3492493A4 (en) * 2016-07-28 2020-03-18 Kaneka Corporation METHOD FOR PRODUCING AN ANTIBODY FRAGMENT
EP3774882A1 (en) * 2018-03-29 2021-02-17 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies

Also Published As

Publication number Publication date
EP4126900A4 (en) 2024-05-29
AU2021244846A1 (en) 2022-11-24
JP2023518905A (ja) 2023-05-08
US20240262928A1 (en) 2024-08-08
CN115551877A (zh) 2022-12-30
BR112022019076A2 (pt) 2023-01-10
CA3176109A1 (en) 2021-09-30
WO2021191684A1 (en) 2021-09-30
US20240262925A1 (en) 2024-08-08
JP7817945B2 (ja) 2026-02-19
US20260035474A1 (en) 2026-02-05
EP4126900A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP7744391B2 (ja) 抗ｖｅｇｆタンパク質組成物及びその製造方法
AU2025287335A1 (en) Continuous manufacturing process for bispecific antibody products
US20160251441A1 (en) Antibody purification
CN113583112B (zh) Aav特异性抗体及其应用
JP2022546002A (ja) ４価の対称型二重特異性抗体
KR20250048376A (ko) 바이러스 오염물을 불활성화하는 방법
US20260035474A1 (en) Composition and method
AU2020221649B2 (en) Producing compositions comprising two or more antibodies.
US20250171536A1 (en) Methods of Bone Marrow Conditioning
CN114057878B (zh) 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
CA3231124A1 (en) Antibodies targeting ccr2
CN114437204A (zh) 一种抗体或Fc融合蛋白的纯化方法
CN114920842B (zh) 特异性结合pv-1蛋白的抗体或其抗原结合片段及其应用
WO2025218552A1 (en) Anti-interleukin-6 receptor antibody and use thereof
HK40120824A (zh) 亲液剂用以提高亲和色谱纯化步骤的产率的用途
AU2023291634A1 (en) Follistatin fusion proteins
CN119998329A (zh) 多特异性多肽复合物
CN119384426A (zh) 亲液剂用以提高亲和色谱纯化步骤的产率的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221026

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application